Greenwich LifeSciences secured European Medicines Agency clearance to enroll HLA-A02 and non-HLA-A02 patients in the same randomized arms of FLAMINGO-01.
Protocol alignment enables all 170-180 US and European sites to enroll both groups through the first interim analysis, boosting enrollment capacity.
The company now targets a combined analysis to support potential approval across both HLA populations, expanding the addressable market for GP2.
GLSI•
